Skip to content

Gain the advantage with high-throughput screening of iPSC-derived models

Pair Ncardia’s iPSC-derived disease models and high-throughput screenings to get clinically relevant readouts earlier in drug discovery

Get Started

At Ncardia, our assays are developed by an expert team who ensures an efficient development process and delivery of robust and reproducible outcomes that help advance your project. Our customized high-throughput phenotypic screenings are based on physiologically relevant iPSC models and focus on the modulation of disease-linked phenotypes. This strategy enables both testing compounds’ efficacy and safety in human biology earlier and screening with readouts similar to the ones used in clinical trials, which helps you narrow in on your compounds that have a higher probability of success.

Benefits of Ncardia Screening

Custom assays

Evaluate disease-specific phenotypes with the most relevant readouts

Increased chance of success

Consistent and clinically relevant outcomes

Shorter time-to-market

Select compounds with high
probability of clinical success

Efficacy and safety screening with
iPSC-based in vitro models

At every stage of your drug discovery project – whether it’s target identification, lead finding or safety assessment – a reliable assay is the key to success. Our phenotypic screening of iPSC-based disease models makes it easier to extrapolate to the clinical situation.


Screening that passes
the toughest tests

As more and more drug discovery innovators look to capitalize on the unique value only iPSCs can deliver, they look to Ncardia as the uniquely qualified collaborator to join them on their all-important journeys. We’re ready to help make your next step the very best it can be. So let’s start with a conversation – about your vision, goals and expectations for your drug discovery projects.

Jessica, scientist Screening expert
Jessica, screening expert